AbbVie, Enanta Get OK for First and Only Treatment for People with Acute Hepatitis C Virus

 

• MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*†

• FDA Approval Now Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis

• If Left Untreated, Patients with Acute HCV Could Progress to Chronic Disease, Including Cirrhosis or Liver Cancer2

• Glecaprevir, One of the Two Direct-Acting Antivirals in MAVYRET®, was Discovered by Enanta and Developed and Commercialized by AbbVie

https://finance.yahoo.com/news/enanta-pharmaceuticals-partner-abbvie-receives-163400919.html